Navigation Links
EORTC BOS 2 trial opens for patients with resectable liver metastases from colorectal cancer
Date:6/4/2013

Colorectal cancer (CRC) is the second most frequent cause of cancer-related mortality in both Europe and the United States. Treatment for patients with resectable hepatic metastases from colorectal cancer consists of surgery combined with chemotherapy, but recurrence is observed in two thirds of these patients. In order to improve the outcome for these patients, EORTC trial 40091 BOS 2 will test the efficacy of adding bevacizumab or panitumumab to the standard treatment, peri-operative FOLFOX 4 chemotherapy.

Bevacizumab is a monoclonal antibody which targets the vascular endothelial growth factor (VEGF), and blocking VEGF could deprive the cancer of required nutrients. Panitumumab targets the epidermal growth factor receptor (EGFR). EGFR gene expression is upregulated in approximately 60 to 80% of CRC cases, and this has been linked to poor survival.

Dr. Bernard Nordlinger, CHU Ambroise Pare AP-HP, Boulogne-Billancourt and Coordinator of this study, says "The objective of this trial is to determine a new standard of care for these patients." The randomized phase 2 EORTC trial will investigate if treatment with perioperative modified FOLFOX6 plus either bevacizumab or panitumumab improves progression-free survival and pathological response in patients with up to eight resectable liver metastases resulting from wild type KRAS CRC as compared to treatment with perioperative modified FOLFOX 6 alone.

Dr. Stephane Benoist, Assistance Publique, Hpitaux de Paris, Hopital De Bicetre AP-HP, Le Kremlin Bicetre and co-Coordinator of this study, says "Following the EPOC study, perioperative FOLFOX chemotherapy became the new standard of care in many countries for patients with resectable colorectal liver metastases. Nevertheless, most patients developed recurrence despite perioperative FOLFOX chemotherapy. One of the ways to improve long term prognosis is to intensify the perioperative chemotherapy. The BOS 2 study addresses a major clinical ques
'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients
2. Markers in Cancer, a joint meeting by ASCO, EORTC & NCI, 7-9 Nov 2013 (diagnostic tutorial on 5-7)
3. EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
4. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
5. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
6. New Hepatitis C Clinical Trial Now Enrolling at Avail Clinical Research near Orlando, Florida; Accepting M/F Patients with Hep C Age 18-65
7. Low Back Pain Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with Chronic Low Back Pain Age 18-80
8. DePuy ASR Hip Implant Lawyers at Wright & Schulte LLC Pleased with Judge’s Decision to Uphold $8.3 Million Award in California DePuy ASR Hip Lawsuit Trial
9. True-Dose Pets Launches New Trial-Sized Product Line
10. Vaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Pretrial Order in Federal Transvaginal Mesh Litigation
11. CureLauncher Introduces Personalized Clinical Trial Matching Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... CAMBRIDGE, Mass., March 11 Idenix,Pharmaceuticals, Inc. (Nasdaq: ... corporate overview at the upcoming Eleventh Annual Lehman,Brothers Global ... ET at the Loews Miami Beach Hotel in South ... the company presentation can be,accessed under "Calendar of Events" ...
... also increases odds, study finds , , TUESDAY, March ... for glaucoma and those with high pressure in their ... a new study suggests. , "Glaucoma is one of ... from Stony Brook University in Stony Brook, N.Y., wrote ...
... help, at least for a while, study finds, , , TUESDAY, ... are often dismal, but a new study finds that when ... able to keep off more weight. , The study ... more likely to maintain their weight loss than people who ...
... SAN DIEGO, March 11 Dr. Fred Baughman released ... with you, that "Illness of the brain must be ... of Representatives have,passed a mental health parity bill. The ... diagnoses are actual diseases, disorders or,illnesses of the brain. ...
... time when several U.S. health insurers have discontinued payment ... colonoscopies, physicians at the University of Pennsylvania School of ... the drug could both save millions of health care ... pain relief. , The researchers studied two groups of ...
... Women with Knowledge and Tools for ... Lifelong Sobriety, CENTER ... a new addiction recovery resource for women,A Woman,s Guide to Recovery. Written ... offers an honest and direct,approach for women seeking solace from the grips ...
Cached Medicine News:Health News:Glaucoma May Boost Cardiovascular Death Risk in Blacks 2Health News:Personal Contact Helps Maintain Weight Loss 2Health News:Personal Contact Helps Maintain Weight Loss 3Health News:Open Letter to Speaker Pelosi on Approval of Mental Health Parity 2Health News:Open Letter to Speaker Pelosi on Approval of Mental Health Parity 3Health News:Penn research offers road map to safer pain control, cost savings during colonoscopies 2Health News:Hazelden Publishing Unveils Valuable New Resource for Women Seeking Recovery From Addiction 2Health News:Hazelden Publishing Unveils Valuable New Resource for Women Seeking Recovery From Addiction 3
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
(Date:1/23/2015)... January 23, 2015 Heptares Therapeutics, the clinical-stage ... announce that the Malcolm Campbell Memorial Prize for ... President of Chemistry), Fiona Marshall (Chief Scientific Officer ... and co-founder) for the seminal contributions to GPCR drug discovery ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... Treated Using Next Generation CyberKnife System at Oklahoma ... ... ARAY ), a global leader in the field of radiosurgery,announced ... Robotic Radiosurgery System that was recently,installed at the Oklahoma CyberKnife, LLC ...
... Explore the Effects of Eligen(R) Delivery Technology and ... in Postmenopausal Women, CEDAR KNOLLS, N.J., Aug. ... announced today that Novartis Pharma AG,has finished recruitment ... and efficacy of Salmon Calcitonin and Emisphere,s proprietary,Eligen(R) ...
Cached Medicine Technology:New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 2New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 3New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 4Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment 2
... provides a new screening, diagnostic, treatment assessment ... management of sleep-related breathing disorders. The Watch-PAT ... need for an ambulatory, reliable, patient friendly ... the great number of OSA sufferers, and ...
... (PTH) is synthesized by the parathyroid ... to decreased extracellular calcium concentrations. PTH ... and decreasing calcium excretion by the ... intact PTH is rapidly degraded into ...
... is produced in the adrenal cortex and, ... DHEA serves as a precursor in testosterone ... androgenic activity, estimated at ~10% that of ... and in adult women, DHEA is an ...
... the adrenal cortex and, to a lesser ... a precursor in testosterone and estrogen synthesis, ... at ~10% that of testosterone [1]. However, ... women, DHEA is an important androgen as ...
Medicine Products: